+44 20 8123 2220
info@marketpublishers.com

NIVOLUMAB - Emerging Insight and Market Forecast - 2030

https://marketpublishers.com/r/NF42DFBDD687EN.html
Date: February 2021
Pages: 30
Price: US$ 3,250.00 (Single User License)
ID: NF42DFBDD687EN

Abstracts

This report can be delivered to the clients within 48 Hours

“NIVOLUMAB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Follicular lymphoma in 7 Major Markets. A detailed picture of the NIVOLUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020 - 2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

OVERVIEW

NIVOLUMAB (Opdivo; anti-PD-1 monoclonal antibody - Medarex/Ono; BMS936558; MDX1106; ONO4538) is a fully human IgG4 monoclonal antibody targeting the programmed cell death1 receptor (PD-1). PD-1 is expressed on the surface of activated lymphocytes and acts as part of an immune checkpoint pathway. PD-1 blockade by nivolumab may activate T-cell responses and promote an anti-tumour immune response. In phase II clinical trials, subjects with relapsed or refractory follicular non-Hodgkin lymphoma were administered nivolumab 3mg/kg intravenously (IV) once every 2 weeks, until disease progression or unacceptable toxicity.

Nivolumab (Opdivo) is licensed in the EU as monotherapy for the treatment of advanced, unresectable or metastatic melanoma in adults (first and second line

+44 20 8123 2220
info@marketpublishers.com

therapy). Nivolumab (Nivolumab BMS) is also licensed for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (second line therapy). It is currently in Phase II for follicular Lymphoma and is being developed by Bristol Myers Squibb.

SCOPE OF THE REPORT

The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.

Elaborated details on regulatory milestones and other development activities have been provided in this report.

The report also highlights the drug research and development activity details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around NIVOLUMAB.

The report contains forecasted sales for NIVOLUMAB till 2030.

Comprehensive coverage of the late-stage emerging therapies (Phase III) for Follicular lymphoma.

The report also features the SWOT analysis with analyst insights and key findings of NIVOLUMAB.

METHODOLOGY

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available

+44 20 8123 2220
info@marketpublishers.com

databases.

NIVOLUMAB Analytical Perspective by DelveInsight

In-depth NIVOLUMAB Market Assessment

This report provides a detailed market assessment of NIVOLUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

NIVOLUMAB Clinical Assessment

The report provides the clinical trials information of NIVOLUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

REPORT HIGHLIGHTS

In the coming years, the market scenario for Follicular lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence NIVOLUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Other emerging products for Follicular lymphoma are giving market competition to NIVOLUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of NIVOLUMAB.

Our in-depth analysis of the forecasted sales data of NIVOLUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their

+44 20 8123 2220
info@marketpublishers.com

therapeutic portfolio by identifying the overall scenario of the NIVOLUMAB.

Key Questions

Which company is developing NIVOLUMAB along with the phase of the clinical study?

What is the technology utilized in the development of NIVOLUMAB?

What is the product type, route of administration and mechanism of action of NIVOLUMAB?

What is the clinical trial status of the study and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NIVOLUMAB development?

What are the key designations that have been granted to NIVOLUMAB?

What is the forecasted market scenario of NIVOLUMAB?

What is the history of NIVOLUMAB and what is its future?

What is the forecasted sales of NIVOLUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how these are giving competition to NIVOLUMAB?

Which are the late-stage emerging therapies under development for the treatment of the Follicular Lymphoma?

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: NIVOLUMAB - Emerging Insight and Market Forecast - 2030
Product link: https://marketpublishers.com/r/NF42DFBDD687EN.html
Price: US$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NF42DFBDD687EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970